OptimizeRx Co. (NASDAQ:OPRX) Receives $15.86 Average PT from Brokerages

OptimizeRx Co. (NASDAQ:OPRX) has been given a consensus recommendation of “Moderate Buy” by the seven research firms that are covering the stock, MarketBeat Ratings reports. One investment analyst has rated the stock with a hold recommendation and six have issued a buy recommendation on the company. The average twelve-month price target among brokers that have issued ratings on the stock in the last year is $15.86.

Several research firms have recently issued reports on OPRX. Stifel Nicolaus reaffirmed a “buy” rating and issued a $13.00 price target on shares of OptimizeRx in a research report on Monday, April 1st. Royal Bank of Canada reaffirmed an “outperform” rating and issued a $17.00 price objective on shares of OptimizeRx in a research report on Monday, April 1st. Finally, JMP Securities reissued a “market outperform” rating and issued a $15.00 target price on shares of OptimizeRx in a report on Tuesday, April 16th.

OptimizeRx Stock Performance

Shares of OPRX opened at $10.91 on Tuesday. The firm has a market capitalization of $198.39 million, a PE ratio of -10.80 and a beta of 1.05. The company has a debt-to-equity ratio of 0.27, a current ratio of 3.04 and a quick ratio of 3.04. The company has a 50-day simple moving average of $11.73 and a two-hundred day simple moving average of $12.18. OptimizeRx has a one year low of $6.92 and a one year high of $16.65.

OptimizeRx (NASDAQ:OPRX) last released its earnings results on Tuesday, April 16th. The company reported $0.11 earnings per share for the quarter. OptimizeRx had a negative net margin of 24.56% and a negative return on equity of 7.72%. The firm had revenue of $28.37 million for the quarter. On average, analysts anticipate that OptimizeRx will post -0.49 EPS for the current fiscal year.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the stock. Nisa Investment Advisors LLC lifted its position in shares of OptimizeRx by 215.0% in the fourth quarter. Nisa Investment Advisors LLC now owns 2,142 shares of the company’s stock valued at $31,000 after acquiring an additional 1,462 shares in the last quarter. Quantbot Technologies LP purchased a new position in shares of OptimizeRx during the third quarter valued at about $49,000. Cetera Trust Company N.A purchased a new stake in shares of OptimizeRx in the fourth quarter worth about $77,000. L2 Asset Management LLC bought a new position in OptimizeRx during the third quarter valued at approximately $95,000. Finally, Tower Research Capital LLC TRC grew its holdings in OptimizeRx by 407.5% during the 4th quarter. Tower Research Capital LLC TRC now owns 6,765 shares of the company’s stock valued at $97,000 after buying an additional 5,432 shares in the last quarter. Institutional investors own 76.47% of the company’s stock.

OptimizeRx Company Profile

OptimizeRx Corporation, a digital health technology company, provides various solutions to life sciences organizations, healthcare providers (HCPs), and patients. Its products and applications include Evidence-Based Physician Engagement solution to assist HCPs in identifying patients who may be qualified for specific therapies, raise awareness of patient access pathways, and identify early indicators of non-adherence among patient populations; and Point of Care Banner messaging solution to deliver a variety of awareness and messaging within the clinical workflow.